Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 3/2021

01-06-2021 | Proton Pump Inhibitors | Research Article

Underutilization of gastrointestinal prophylaxis in high-risk chronic nonsteroidal anti-inflammatory drug users in Korea

Authors: Woo-Youn Kim, Suhyun Lee, Kwanghee Jun, Young-Mi Ah, Ju-Yeun Lee

Published in: International Journal of Clinical Pharmacy | Issue 3/2021

Login to get access

Abstract

Background The increasing use of antithrombotic therapies in older patients has led to an increased risk of gastrointestinal (GI) bleeding in chronic nonsteroidal anti-inflammatory drug (NSAID) users. Therefore, there is a pressing need for GI prophylaxis in these high-risk patients. Objective To analyze prescribing patterns and factors associated with the use of gastroprotective agents (GPAs) among high-risk, chronic NSAID users. Setting National claims database including 20% of the total Korean population aged ≥ 65 years. Method In this cross-sectional study, we identified older adults prescribed traditional NSAIDs for > 90 days and classified them into high- and ultra-high-risk groups if they had one or two or more GI risk factors, respectively. Proton pump inhibitors or misoprostol prescribed for more than 80% of traditional NSAID treatment days was regarded as appropriate GI prophylaxis. Main outcome measure Prevalence and associated factors with appropriate GI prophylaxis. Results Among 69,992 chronic traditional NSAID users, 38.8% and 9.4% belonged to the high and ultra-high-risk groups; 13.2% and 19.9% received appropriate GI prophylaxis, respectively. The most frequently used GPA was histamine H2 antagonists. Multiple NSAID use, concomitant antiplatelets and anticoagulants, and prior GI ulcer history increased the likelihood of receiving appropriate GI prophylaxis. Advanced age (≥ 85 years), indications other than arthritis, and neurology specialists negatively affected appropriate GI prophylaxis use. Conclusion Approximately one in five chronic NSAID users, considered ultra-high risk, are prescribed appropriate GI prophylaxis in Korea. Advanced age, indications, and specialties of the prescriber all need to be considered when selecting target populations for interventions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ. 2013;346:f3195.PubMed Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ. 2013;346:f3195.PubMed
2.
go back to reference Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79.CrossRef Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79.CrossRef
3.
go back to reference Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24(2):121–32.CrossRef Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24(2):121–32.CrossRef
4.
go back to reference Choi DW, Park SC, Chun HJ. Update on NSAIDs related peptic ulcers. Korean J Med. 2014;86(6):664–72.CrossRef Choi DW, Park SC, Chun HJ. Update on NSAIDs related peptic ulcers. Korean J Med. 2014;86(6):664–72.CrossRef
5.
go back to reference Sabzwari SR, Qidwai W, Bhanji S. Polypharmacy in elderly: a cautious trail to tread. J Pak Med Assoc. 2013;63(5):624–7.PubMed Sabzwari SR, Qidwai W, Bhanji S. Polypharmacy in elderly: a cautious trail to tread. J Pak Med Assoc. 2013;63(5):624–7.PubMed
6.
go back to reference Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 1988;109(5):359–63.CrossRef Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 1988;109(5):359–63.CrossRef
7.
go back to reference Dregan A, Ravindrarajah R, Charlton J, Ashworth M, Molokhia M. Long-term trends in antithrombotic drug prescriptions among adults aged 80 years and over from primary care: a temporal trends analysis using electronic health records. Ann Epidemiol. 2018;28(7):440–6.CrossRef Dregan A, Ravindrarajah R, Charlton J, Ashworth M, Molokhia M. Long-term trends in antithrombotic drug prescriptions among adults aged 80 years and over from primary care: a temporal trends analysis using electronic health records. Ann Epidemiol. 2018;28(7):440–6.CrossRef
8.
go back to reference Lanas A, Carrera-Lasfuentes P, Arguedas Y, Garcia S, Bujanda L, Calvet X, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13(5):906-12.e2.CrossRef Lanas A, Carrera-Lasfuentes P, Arguedas Y, Garcia S, Bujanda L, Calvet X, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13(5):906-12.e2.CrossRef
9.
go back to reference Yang M, He M, Zhao M, Zou B, Liu J, Luo LM, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017;33(6):973–80.CrossRef Yang M, He M, Zhao M, Zou B, Liu J, Luo LM, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017;33(6):973–80.CrossRef
10.
go back to reference Yuan J, Tsoi K, Yang M, Wang J, Threapleton D, Yang Z, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016;43(12):1262–75.CrossRef Yuan J, Tsoi K, Yang M, Wang J, Threapleton D, Yang Z, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016;43(12):1262–75.CrossRef
11.
go back to reference Bello AE, Kent JD, Holt RJ. Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons. Phys Sportsmed. 2015;43(3):193–9.CrossRef Bello AE, Kent JD, Holt RJ. Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons. Phys Sportsmed. 2015;43(3):193–9.CrossRef
12.
go back to reference Szeto CC, Sugano K, Wang JG, Fujimoto K, Whittle S, Modi GK, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut. 2020;69(4):617–29.CrossRef Szeto CC, Sugano K, Wang JG, Fujimoto K, Whittle S, Modi GK, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut. 2020;69(4):617–29.CrossRef
13.
go back to reference Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, Hunt RH. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis–an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015;19(13):55.CrossRef Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, Hunt RH. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis–an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015;19(13):55.CrossRef
14.
go back to reference Medlock S, Eslami S, Askari M, Taherzadeh Z, Opondo D, de Rooij SE, et al. Co-prescription of gastroprotective agents and their efficacy in elderly patients taking nonsteroidal anti-inflammatory drugs: a systematic review of observational studies. Clin Gastroenterol Hepatol. 2013;11(10):1259-69.e10.CrossRef Medlock S, Eslami S, Askari M, Taherzadeh Z, Opondo D, de Rooij SE, et al. Co-prescription of gastroprotective agents and their efficacy in elderly patients taking nonsteroidal anti-inflammatory drugs: a systematic review of observational studies. Clin Gastroenterol Hepatol. 2013;11(10):1259-69.e10.CrossRef
15.
go back to reference Dincer D, Ulukal Karanci E, Akin M, Adanir H. NSAID, antiaggregant, and/or anticoagulant-related upper gastrointestinal bleeding: Is there any change in prophylaxis rate after a 10-year period? Turk J Gastroenterol. 2019;30(6):505–10.PubMedPubMedCentral Dincer D, Ulukal Karanci E, Akin M, Adanir H. NSAID, antiaggregant, and/or anticoagulant-related upper gastrointestinal bleeding: Is there any change in prophylaxis rate after a 10-year period? Turk J Gastroenterol. 2019;30(6):505–10.PubMedPubMedCentral
16.
go back to reference Kim TJ, Kim ER, Hong SN, Kim YH, Lee YC, Kim HS, et al. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep. 2019;9(1):11696.CrossRef Kim TJ, Kim ER, Hong SN, Kim YH, Lee YC, Kim HS, et al. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep. 2019;9(1):11696.CrossRef
17.
go back to reference Kim L, Kim JA, Kim S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health. 2014;36:e2014008.CrossRef Kim L, Kim JA, Kim S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health. 2014;36:e2014008.CrossRef
18.
go back to reference van Soest EM, Sturkenboom M, Dieleman J, Verhamme KM, Siersema P, Kuipers E, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther. 2007;26(2):265–75.CrossRef van Soest EM, Sturkenboom M, Dieleman J, Verhamme KM, Siersema P, Kuipers E, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther. 2007;26(2):265–75.CrossRef
19.
go back to reference Han MH, Noh E, Nam JH, Lee SW, Lee E-K. Prescribing pattern and safety analysis of nonsteroidal anti-inflammatory drug and gastro-protective agent following reimbursement guidelines relaxation. Korean J Clin Pharm. 2017;27(4):250–7.CrossRef Han MH, Noh E, Nam JH, Lee SW, Lee E-K. Prescribing pattern and safety analysis of nonsteroidal anti-inflammatory drug and gastro-protective agent following reimbursement guidelines relaxation. Korean J Clin Pharm. 2017;27(4):250–7.CrossRef
20.
go back to reference Warle-van Herwaarden MF, Koffeman AR, Valkhoff VE, t Jong GW, Kramers C, Sturkenboom MC, et al. Time-trends in the prescribing of gastroprotective agents to primary care patients initiating low-dose aspirin or non-steroidal anti-inflammatory drugs: a population-based cohort study. Br J Clin Pharmacol. 2015;80(3):589–98.CrossRef Warle-van Herwaarden MF, Koffeman AR, Valkhoff VE, t Jong GW, Kramers C, Sturkenboom MC, et al. Time-trends in the prescribing of gastroprotective agents to primary care patients initiating low-dose aspirin or non-steroidal anti-inflammatory drugs: a population-based cohort study. Br J Clin Pharmacol. 2015;80(3):589–98.CrossRef
21.
go back to reference Hoffmann F, Glaeske G, Schmiemann G. Underuse of proton-pump inhibitors in older patients newly starting NSAID treatment. Int J Clin Pract. 2015;69(7):791–5.CrossRef Hoffmann F, Glaeske G, Schmiemann G. Underuse of proton-pump inhibitors in older patients newly starting NSAID treatment. Int J Clin Pract. 2015;69(7):791–5.CrossRef
22.
go back to reference Szabo IL, Matics R, Hegyi P, Garami A, Illes A, Sarlos P, et al. PPIs prevent aspirin-induced gastrointestinal bleeding better than H2RAs. a systematic review and meta-analysis. J Gastrointest Liver Dis. 2017;26(4):395–402.CrossRef Szabo IL, Matics R, Hegyi P, Garami A, Illes A, Sarlos P, et al. PPIs prevent aspirin-induced gastrointestinal bleeding better than H2RAs. a systematic review and meta-analysis. J Gastrointest Liver Dis. 2017;26(4):395–402.CrossRef
23.
go back to reference O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8.CrossRef O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8.CrossRef
24.
go back to reference Tuskey A, Peura D. The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S6.CrossRef Tuskey A, Peura D. The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S6.CrossRef
25.
go back to reference Kim JH, Park S-H, Cho C-S, Lee ST, Yoo W-H, Kim SK, et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver. 2014;8(4):371.CrossRef Kim JH, Park S-H, Cho C-S, Lee ST, Yoo W-H, Kim SK, et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver. 2014;8(4):371.CrossRef
26.
go back to reference Lee OY, Kang DH, Lee DH, Chung IK, Jang JY, Kim JI, et al. A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment. Arch Pharm Res. 2014;37(10):1308–16.CrossRef Lee OY, Kang DH, Lee DH, Chung IK, Jang JY, Kim JI, et al. A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment. Arch Pharm Res. 2014;37(10):1308–16.CrossRef
27.
go back to reference Laine L, Connors L, Griffin MR, Curtis SP, Kaur A, Cannon CP. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther. 2009;30(7):767–74.CrossRef Laine L, Connors L, Griffin MR, Curtis SP, Kaur A, Cannon CP. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther. 2009;30(7):767–74.CrossRef
28.
go back to reference Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105(12):2533–49.CrossRef Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105(12):2533–49.CrossRef
29.
go back to reference Butler E, Moller MH, Cook O, Granholm A, Penketh J, Rygard SL, et al. The effect of systemic corticosteroids on the incidence of gastrointestinal bleeding in critically ill adults: a systematic review with meta-analysis. Intensive Care Med. 2019;45(11):1540–9.CrossRef Butler E, Moller MH, Cook O, Granholm A, Penketh J, Rygard SL, et al. The effect of systemic corticosteroids on the incidence of gastrointestinal bleeding in critically ill adults: a systematic review with meta-analysis. Intensive Care Med. 2019;45(11):1540–9.CrossRef
30.
go back to reference Chou CL, Perng DW, Lin TL, Lin AM, Chen TJ, Wu MS, et al. Analysis of prescription pattern and guideline adherence in the management of asthma among medical institutions and physician specialties in Taiwan between 2000 and 2010. Clin Ther. 2015;37(10):2275–85.CrossRef Chou CL, Perng DW, Lin TL, Lin AM, Chen TJ, Wu MS, et al. Analysis of prescription pattern and guideline adherence in the management of asthma among medical institutions and physician specialties in Taiwan between 2000 and 2010. Clin Ther. 2015;37(10):2275–85.CrossRef
31.
go back to reference Wilcox CM, Allison J, Benzuly K, Borum M, Cryer B, Grosser T, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol. 2006;4(9):1082–9.CrossRef Wilcox CM, Allison J, Benzuly K, Borum M, Cryer B, Grosser T, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol. 2006;4(9):1082–9.CrossRef
Metadata
Title
Underutilization of gastrointestinal prophylaxis in high-risk chronic nonsteroidal anti-inflammatory drug users in Korea
Authors
Woo-Youn Kim
Suhyun Lee
Kwanghee Jun
Young-Mi Ah
Ju-Yeun Lee
Publication date
01-06-2021
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 3/2021
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01176-0

Other articles of this Issue 3/2021

International Journal of Clinical Pharmacy 3/2021 Go to the issue

Editorial

Editorial

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine